Targeting TRAFs for Therapeutic Intervention

  • Juan M. Zapata
  • Sophie Lefebvre
  • John C. Reed
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 597)


TNF-receptor associated factors (TRAFs) are the molecules that upon engagement of the TNF-receptor (TNFR) by a TNF-family ligand come first in contanct with the activated TNFR, initially acting as docking molecules for kinases and other effector proteins that are recruited to the activated receptor. TRAFs later regulate the subcellular relocalization of the receptor-ligand complex and finally they modulate the extent of the response by controlling the degradation of key proteins in the pathway.

In this chapter, we review the involvement of different TRAF family members in the etiology of a variety of pathologies and address the question of whether the use of TNFR-mimic-peptides or small molecule modulators targeting TRAFs might be suitable for therapeutic intervention, discussing the advantages and disadvantages of this strategy.


Chronic Lymphocytic Leukemia Splenic Marginal Zone Lymphoma Hypohidrotic Ectodermal Dysplasia Small Molecule Modulator Latent Infection Membrane Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chung JY, Park YC, Ye H et al. All TRAFs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115:679–688.PubMedGoogle Scholar
  2. 2.
    Zapata JM. TNF-receptor-associated factors as targets for drug development. Expert Opin Ther Targets 2003; 7(3):411–425.PubMedGoogle Scholar
  3. 3.
    Ye H, Arron JR, Lamothe B et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002; 418:443–447.PubMedGoogle Scholar
  4. 4.
    Xu LG, Li LY, Shu HB. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem 2004; 279(17):17278–17282.PubMedGoogle Scholar
  5. 5.
    Park Y, Burkitt V, Villa A et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398:533–538.PubMedGoogle Scholar
  6. 6.
    Ye H, Park Y, Kreishman M et al. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 1999; 4:321–330.PubMedGoogle Scholar
  7. 7.
    Ni CZ, Welsh K, Leo E et al. Molecular basis for CD40 signaling mediated by Traf3. Proc Natl Acad Sci USA 2000; 97:10395–10399.PubMedGoogle Scholar
  8. 8.
    Li C, Norris PS, Ni CZ et al. Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J Biol Chem 2003; 278(50):50523–50529.PubMedGoogle Scholar
  9. 9.
    Ni CZ, Oganesyan G, Welsh K et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: Implications for intracellular signaling regulation. J Immunol 2004; 173(12):7394–7400.PubMedGoogle Scholar
  10. 10.
    Sutherland CL, Krebs DL, Gold MR. An 11-amino acid sequence in the cytoplasmic domain of CD40 is sufficient for activation of c-Jun N-terminal kinase, activation of MAPKAP kinase-2, phosphorylation of I kappa B alpha, and protection of WEHI-231 cells from anti-IgM-induced growth arrest. J Immunol 1999; 162(8):4720–4730.PubMedGoogle Scholar
  11. 11.
    Zapata JM, Krajewska M, Morse IIIrd HC et al. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci USA 2004; 101(47):16600–16605.PubMedGoogle Scholar
  12. 12.
    Grech AP, Amesbury M, Chan T et al. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21(5):629–642.PubMedGoogle Scholar
  13. 13.
    Lee SY, Reichlin A, Santana A et al. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997; 7:703–713.PubMedGoogle Scholar
  14. 14.
    Izban KF, Ergin M, Martinez RL et al. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol 2000; 13:1324–1331.PubMedGoogle Scholar
  15. 15.
    Murray PG, Flavell JR, Baumforth KR et al. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin’s disease. J Pathol 2001; 194:158–164.PubMedGoogle Scholar
  16. 16.
    Horie R, Watanabe T, Ito K et al. Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells. Am J Pathol 2002; 160(5):1647–1654.PubMedGoogle Scholar
  17. 17.
    Habelhah H, Takahashi S, Cho SG et al. Ubiquitination and translocation of TRAF2 is required for activation of JNK but not of p38 or NF-kappaB. EMBO J 2004; 23(2):322–332.PubMedGoogle Scholar
  18. 18.
    Staudt LM. The molecular and cellular origins of Hodgkin’s disease. J Exp Med 2000; 191(2):207–212.PubMedGoogle Scholar
  19. 19.
    Nonaka M, Horie R, Itoh K et al. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 2005.Google Scholar
  20. 20.
    Zapata JM, Krajewska M, Krajewski S et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000; 165:5084–5096.PubMedGoogle Scholar
  21. 21.
    Zapata JM, Reed JC. TRAF1: Lord without a RING. Science STKE, 2002, (; 2002/133/pe27n).
  22. 22.
    Durkop H, Foss HD, Demel G et al. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin’s disease and Epstein-Barr virus-transformed lymphoid cells. Blood 1999; 93:617–623.PubMedGoogle Scholar
  23. 23.
    Murray PG, Swinnen LJ, Flavell JR et al. Frequent expression of the tumor necrosis factor receptor-associated factor 1 in latent membrane protein 1-positive posttransplant lymphoproliferative disease and HIV-associated lymphomas. Hum Pathol 2001; 32:963–969.PubMedGoogle Scholar
  24. 24.
    Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001; 20:6482–6491.PubMedGoogle Scholar
  25. 25.
    Wang C, Mayo M, Korneluk R et al. NK-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress capase-8 activation. Science 1998; 281:1680–1683.PubMedGoogle Scholar
  26. 26.
    Tsitsikov EN, Laouini D, Dunn IF et al. TRAF1 is a negative regulator of TNF signaling: Enhanced TNF signaling in TRAF1-deficient mice. Immunity 2001; 15:647–657.PubMedGoogle Scholar
  27. 27.
    Arron JR, Pewzner-Jung Y, Walsh MC et al. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J exp Med 2002; 196(7):923–934.PubMedGoogle Scholar
  28. 28.
    Speiser DE, Lee SY, Wong B et al. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J Exp Med 1997; 185:1777–1783.PubMedGoogle Scholar
  29. 29.
    Guiet C, Silvestri E, De Smaele E et al. c-FLIP efficiently rescues TRAF-2-/- cells from TNF-induced apoptosis. Cell Death and Differ 2002; 9:138–144.Google Scholar
  30. 30.
    Fotin-Mleczek M, Henkler F, Hausser A et al. TNF receptor associated factor (TRAF) 1 regulates CD40-induced TRAF2-mediated NF-kappa B activation. J Biol Chem 2003.Google Scholar
  31. 31.
    Pryhuber GS, Huyck HL, Roper JM et al. Acute tumor necrosis factor-alpha-induced liver injury in the absence of tumor necrosis factor receptor-associated factor 1 gene expression. Am J Pathol 2005; 166(6):1637–1645.PubMedGoogle Scholar
  32. 32.
    Shanahan JC, St Clair W. Tumor necrosis factor-alpha blockade: A novel therapy for rheumatic disease. Clin Immunol 2002; 103(3 Pt 1):231–242.PubMedGoogle Scholar
  33. 33.
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347(6):417–429.PubMedGoogle Scholar
  34. 34.
    Yeh WC, Shahinian A, Speiser D et al. Early lethality, functional NF-KB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997; 7:715–725.PubMedGoogle Scholar
  35. 35.
    Nguyen LT, Duncan GS, Mirtsos C et al. TRAF2 deficiency results in hyperactivity of certain TNRFR1 signals and impairment of CD40-mediated responses. Immunity 1999; 11:379–389.PubMedGoogle Scholar
  36. 36.
    Cannons JL, Bertram EM, Watts TH. Cutting edge: Profound defect in T cell responses in TNF receptor-associated factor 2 dominant negative mice. J Immunol 2002; 169(6):2828–2831.PubMedGoogle Scholar
  37. 37.
    Wajant H, Scheurich P. Tumor necrosis factor receptor-associated factor (TRAF) 2 and its role in TNF signaling. Int J Biochem Cell Biol 2001; 33:19–32.PubMedGoogle Scholar
  38. 38.
    MacLachlan TK, Giordano A. TRAF2 expression in differentiated muscle. J Cell Biochem 1998; 71(4):461–466.PubMedGoogle Scholar
  39. 39.
    Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1(1):50–58.PubMedGoogle Scholar
  40. 40.
    Lin Y, Ryan J, Lewis J et al. TRAF2 exerts ints antiapoptotic effect by regulating the expression of Kruppel-like factor LKLF. Mol Cell Biol 2003; 23(16):5849–5856.PubMedGoogle Scholar
  41. 41.
    Williams H, Crawford DH. Epstein-barr virus: Impact of scientific advance on clinical practice. Blood 2005.Google Scholar
  42. 42.
    Cahir McFarland ED, Izumi KM, Mosialos G. Epstein-barr virus transformation: Involvement of latent membrane protein 1-mediated activation of NF-kappaB Oncogene 1999; 18(49):6959–6964.PubMedGoogle Scholar
  43. 43.
    Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin Cancer Biol 2001; 11(6):435–444.PubMedGoogle Scholar
  44. 44.
    Kulwichit W, Edwards RH, Davenport EM et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998; 95(20):11963–11968.PubMedGoogle Scholar
  45. 45.
    Kang MS, Lu H, Yasui T et al. Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci USA 2005; 102(3):820–825.PubMedGoogle Scholar
  46. 46.
    Hatzivassiliou E, Mosialos G. Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Front Biosci 2002; 7:d319–329.PubMedGoogle Scholar
  47. 47.
    Bishop GA, Busch LK. Molecular mechanisms of B-lymphocyte transformation by Epstein-Barr virus. Microbes Infect 2002; 4(8):853–857.PubMedGoogle Scholar
  48. 48.
    Mosialos G, Birkenback M, Yalamanchili R et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. CELL 1995; 80(3):389–399.PubMedGoogle Scholar
  49. 49.
    Devergne O, Hatzivassiliou E, Izumi KM et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lympyhocyte transformation: Role in NF-κB activation. Mol Cell Biol 1996; 16:7098–7108.PubMedGoogle Scholar
  50. 50.
    Brodeur SR, Cheng G, Baltimore D et al. Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 1997; 272(32):19777–19784.PubMedGoogle Scholar
  51. 51.
    Bishop GA, Hostager BS. Signaling by CD40 and its mimics in B cell activation. Immunol Res 2001; 24(2):97–109.PubMedGoogle Scholar
  52. 52.
    Lam N, Sugden B. CD40 and its viral mimic, LMP1: Similar means to different ends. Cell Signal 2003; 15(1):9–16.PubMedGoogle Scholar
  53. 53.
    Uchida J, Yasui T, Takaoka-Shichijo Y et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286(5438):300–303.PubMedGoogle Scholar
  54. 54.
    Brown KD, Hostager BS, Bishop GA. Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med 2001; 193(8):943–954.PubMedGoogle Scholar
  55. 55.
    Higuchi M, Izumi KM, Kieff E. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: Protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci USA 2001;98(8):4675–4680.PubMedGoogle Scholar
  56. 56.
    Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 2000; 275(20):15392–15398.PubMedGoogle Scholar
  57. 57.
    Ardila-Osorio H, Pioche-Durieu C, Puvion-Dutilleul F et al. TRAF interactions with raft-like buoyant complexes, better than TRAF rates of degradation, differentiate signaling by CD40 and EBV latent membrane protein 1. Int J Cancer 2005; 113(2):267–275.PubMedGoogle Scholar
  58. 58.
    Wu S, Xie P, Welsh K et al. LMP1 protein from the Epstein-Barr virus is a structural CD40 decoy in B lymphocytes for binding to TRAF3. J Biol Chem 2005; 280(39):33620–33626.PubMedGoogle Scholar
  59. 59.
    Eliopoulos AG, Waites ER, Blake SM et al. TRAF1 is a critical regulator of JNK signaling by the TRAF-binding domain of the Epstein-Barr virus-encoded latent infection membrane protein 1 but not CD40. J Virol 2003; 77(2):1316–1328.PubMedGoogle Scholar
  60. 60.
    Schultheiss U, Puschner S, Kremmer E et al. TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J 2001; 20(20):5678–5691.PubMedGoogle Scholar
  61. 61.
    Luftig M, Yasui T, Soni V et al. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci USA 2004; 101(1):141–146.PubMedGoogle Scholar
  62. 62.
    Wu L, Nakano H, Wu Z. The CTAR2 domain of the Epstein-Barr virus-encoded latent membrane protein 1 activates NF-kappa B through TRAF6 and TAK1. J Biol Chem 2005.Google Scholar
  63. 63.
    Eliopoulos AG, Dawson CW, Mosialos G et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene 1996; 13(10):2243–2254.PubMedGoogle Scholar
  64. 64.
    Xie P, Hostager BS, Bishop GA. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B lymphocytes. J Exp Med 2004; 199(5):661–671.PubMedGoogle Scholar
  65. 65.
    Xie P, Bishop GA. Roles of TNF receptor-associated factor 3 in signaling to B lymphocytes by carboxyl-terminal activating regions 1 and 2 of the EBV-encoded oncoprotein latent membrane protein 1. J Immunol 2004; 173(9):5546–5555.PubMedGoogle Scholar
  66. 66.
    Ruiz-Ballesteros E, Mollejo M, Rodriguez A et al. Splenic marginal zone lymphoma. Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106(5):1831–1838.PubMedGoogle Scholar
  67. 67.
    Hauer J, Puschner S, Ramakrishnan P et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-{kappa}B pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102(8):2874–2879.PubMedGoogle Scholar
  68. 68.
    Leo E, Welsh K, Matsuzawa S et al. Differential requirements for TRAF-family proteins in CD40-mediated induction of NF-κB and JNK activation. J Biol Chem 1999; 274:22414–22274.PubMedGoogle Scholar
  69. 69.
    Nakano H, Oshima H, Chung W et al. TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem 1996; 271:14661–14664.PubMedGoogle Scholar
  70. 70.
    Tada K, Okazaki T, Sakon S et al. Critical roles of TRAF2 and TRAF5 in TNF-induced NF-κB activation and protection from cell death. J Biol Chem 2001; 276:36530–36534.PubMedGoogle Scholar
  71. 71.
    Hostager B, Bishop G. Contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol 1999; 162:6307–6311.PubMedGoogle Scholar
  72. 72.
    Hsu BL, Harless SM, Lindsley RC et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168(12):5993–5996.PubMedGoogle Scholar
  73. 73.
    Rolink AG, Tschopp J, Schneider P et al. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002; 32(7):2004–2010.PubMedGoogle Scholar
  74. 74.
    Mackay F, Schneider P, Rennert P et al. BAFF AND APRIL: A tutorial on B cell survival. Annu Rev Immunol 2003; 21:231–264.PubMedGoogle Scholar
  75. 75.
    Sekigawa I, Kaneko H, Hishikawa T et al. HIV infection and SLE: Their pathogenic relationship. Clin Exp Rheumatol 1998; 16(2):175–180.PubMedGoogle Scholar
  76. 76.
    Novak AJ, Darce JR, Arendt BK et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival. Blood 2004; 103(2):689–694.PubMedGoogle Scholar
  77. 77.
    Moreaux J, Legouffe E, Jourdan E et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103(8):3148–3157.PubMedGoogle Scholar
  78. 78.
    He B, Chadburn A, Jou E et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172(5):3268–3279.PubMedGoogle Scholar
  79. 79.
    Novak AJ, Grote DM, Stenson M et al. Expression of BLyS and its receptors in B-cell nonHodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 2004; 104(8):2247–2253.PubMedGoogle Scholar
  80. 80.
    Novak AJ, Bram RJ, Kay NE et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood 2002; 100(8):2973–2979.PubMedGoogle Scholar
  81. 81.
    Kern C, Cornuel JF, Billard C et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004; 103(2):679–688.PubMedGoogle Scholar
  82. 82.
    Nishio M, Endo T, Tsukada N et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005; 106(3):1012–1020.PubMedGoogle Scholar
  83. 83.
    Mackay IR, Rose NR. Autoimmunity and lymphoma: Tribulations of B cells. Nat Immunol 2001; 2(9):793–795.PubMedGoogle Scholar
  84. 84.
    Mackay F, Woodcock SA, Lawton P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190(11):1697–1710.PubMedGoogle Scholar
  85. 85.
    Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404:995–999.PubMedGoogle Scholar
  86. 86.
    Khare SD, Sarosi I, Xia XZ et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97(7):3370–3375.PubMedGoogle Scholar
  87. 87.
    Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002; 109(1):59–68.PubMedGoogle Scholar
  88. 88.
    Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20(6):785–798.PubMedGoogle Scholar
  89. 89.
    Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20(4):441–453.PubMedGoogle Scholar
  90. 90.
    Xu LG, Shu HB. TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production. J Immunol 2002; 169(12):6883–6889.PubMedGoogle Scholar
  91. 91.
    Morrison MD, Reiley W, Zhang M et al. An atypical TRAF-binding motif of BAFF receptor mediates induction of the noncanonical NF-kB signaling pathway. J Biol Chem 2005.Google Scholar
  92. 92.
    Claudio E, Brown K, Park S et al. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 2002; 3(10):958–965.PubMedGoogle Scholar
  93. 93.
    Kayagaki N, Yan M, Seshasayee D et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; 17(4):515–524.PubMedGoogle Scholar
  94. 94.
    Liao G, Zhang M, Harhaj EW et al. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem 2004; 279(25):26243–26250.PubMedGoogle Scholar
  95. 95.
    Krajewski S Zapata JM, Krajewski M et al. Immunohistochemical analysis of in vivo patterns of TRAF-3 expression, a member of the TNF receptor-associated factor family. J Immunol 1997; 159:5841–5852.PubMedGoogle Scholar
  96. 96.
    Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197–216.PubMedGoogle Scholar
  97. 97.
    Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5(10):987–995.PubMedGoogle Scholar
  98. 98.
    Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect 2004; 6(15):1388–1394.PubMedGoogle Scholar
  99. 99.
    O’Neill LA, Dinarello CA. The IL-1 receptor/toll-like receptor superfamily: Crucial receptors for inflammation and host defense. Immunol Today 2000; 21(5):206–209.Google Scholar
  100. 100.
    Dinarello CA. Proinflammatory cytokines. Chest 2000; 118(2):503–508.PubMedGoogle Scholar
  101. 101.
    Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5(10):975–979.PubMedGoogle Scholar
  102. 102.
    Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1(2):135–145.PubMedGoogle Scholar
  103. 103.
    Lomaga M, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999; 13:1015–1024.PubMedGoogle Scholar
  104. 104.
    Kobayashi T, Walsh PT, Walsh MC et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003; 19(3):353–363.PubMedGoogle Scholar
  105. 105.
    Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes to Cells 1999; 4:353–362.PubMedGoogle Scholar
  106. 106.
    Dunne A, O’Neill LA. Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett 2005; 579(15):3330–3335.PubMedGoogle Scholar
  107. 107.
    Kobayashi T, Walsh MC, Choi Y, The role of TRAF6 in signal transduction and the immune response. Microbes Infect 2004; 6(14):1333–1338.PubMedGoogle Scholar
  108. 108.
    Calandra T. Pathogenesis of septic shock: Implications, for prevention and treatment. J Chemother 2001; 13(1):173–180, (Spec No 1).PubMedGoogle Scholar
  109. 109.
    Manocha S, Feinstein D, Kumar A. Novel therapies for sepsis: Antiendotoxin therapies. Expert Opin Investig Drugs 2002; 11(12):1795–1812.PubMedGoogle Scholar
  110. 110.
    Knuefermann P, Nemoto S, Baumgarten G et al. Cardiac inflammation and innate immunity in septic shock: Is there a role for toll-like receptors? Chest 2002; 121(4):1329–1336.PubMedGoogle Scholar
  111. 111.
    Knuefermann P, Vallejo J, Mann DL. The role of innate immune responses in the heart in health and disease. Trends Cardiovasc. Med 2004; 14(1):1–7.PubMedGoogle Scholar
  112. 112.
    Oganesyan G, Saha SK, Guo B et al. Critical role of TRAF3 in the Toll-like receptor-dependent and-independent antiviral response. Nature 2005.Google Scholar
  113. 113.
    Hacker H, Redecke V, Blagoev B et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2005.Google Scholar
  114. 114.
    Takeshita F, Ishii KJ, Kobiyama K et al. TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol 2005; 35(8):2477–2485.PubMedGoogle Scholar
  115. 115.
    Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96(7):3540–3545.PubMedGoogle Scholar
  116. 116.
    Gravallese EM, Galson DL, Goldring SR et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res 2001; 3(1):6–12.PubMedGoogle Scholar
  117. 117.
    Armstrong AP, Tometsko ME, Glaccum M et al. A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem 2002; 277(46):44347–44356.PubMedGoogle Scholar
  118. 118.
    Clarke A, Phillips DI, Brown R et al. Clinical aspects of X-linked hypohidrotic ectodermal dysplasia. Arch Dis Child 1987; 62(10):989–996.PubMedGoogle Scholar
  119. 119.
    Pinheiro M, Freire-Maia N. Ectodermal dysplasias: A clinical classification and a causal review. Am J Med Genet 1994; 53(2):153–162.PubMedGoogle Scholar
  120. 120.
    Thesleff I, Mikkola ML. Death receptor signaling giving life to ectodermal organs. Sci STKE 2002; 2002(131):PE22.PubMedGoogle Scholar
  121. 121.
    Wisniewski SA, Kobielak A, Trzeciak WH et al. Recent advances in understanding of the molecular basis of anhidrotic ectodermal dysplasia: Discovery of a ligand, ectodysplasin A and its two receptors. J Appl Genet 2002; 43(1):97–107.PubMedGoogle Scholar
  122. 122.
    Gaide O, Schneider P. Permanent correction of an inherited ectodermal dysplasia with recombinant EDA. Nat Med 2003; 9(5):614–618.PubMedGoogle Scholar
  123. 123.
    Kojima T, Morikawa Y, Copeland NG et al. TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles. J Biol Chem 2000; 275(27):20742–20747.PubMedGoogle Scholar
  124. 124.
    Naito A, Yoshida H, Nishioka E et al. TRAF6-deficient mice display hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA 2002; 99(13):8766–8771.PubMedGoogle Scholar
  125. 125.
    Sinha SK, Zachariah S, Quinones HI et al. Role of TRAF3 and-6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor. J Biol Chem 2002; 277(47):44953–44961.PubMedGoogle Scholar
  126. 126.
    Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795–823.PubMedGoogle Scholar
  127. 127.
    Takasaki W, Kajino Y, Kajino K et al. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor. Nat Biotechnol 1997; 15(12):1266–1270.PubMedGoogle Scholar
  128. 128.
    He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-alpha. Science 2005; 310(5750):1022–1025.PubMedGoogle Scholar
  129. 129.
    Fournel S, Wieckowski S, Sun W et al. C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L. Nat Chem Biol 2005; 1(7):377–382.PubMedGoogle Scholar
  130. 130.
    Prive GG, Melnick A. Specific peptides for the therapeutic targeting of oncogenes. Curr Opin Genet Dev 2005.Google Scholar
  131. 131.
    De Coupade C, Fittipaldi A, Chagnas V et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem J 2005; 390(Pt 2):407–418.PubMedGoogle Scholar
  132. 132.
    Futaki S. Oligoarginine vectors for intracellular delivery: Design and cellular-uptake mechanisms. Biopolymers 2005.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Juan M. Zapata
    • 1
  • Sophie Lefebvre
  • John C. Reed
  1. 1.Burnham Institute for Medical ResearchLa JollaUSA

Personalised recommendations